The in silico screening and X-ray structure analysis of the inhibitor complex of Plasmodium falciparum orotidine 5 0 -monophosphate decarboxylase
Orotidine 5
0 -monophosphate decarboxylase from Plasmodium falciparum (PfOMPDC) catalyses the final step in the de novo synthesis of uridine 5 0 -monophosphate (UMP) from orotidine 5 0 -monophosphate (OMP). A defective PfOMPDC enzyme is lethal to the parasite. Novel in silico screening methods were performed to select 14 inhibitors against PfOMPDC, with a high hit rate of 9%. X-ray structure analysis of PfOMPDC in complex with one of the inhibitors, 4-(2-hydroxy-4-methoxyphenyl)-4-oxobutanoic acid, was carried out to at 2.1 Å resolution. The crystal structure revealed that the inhibitor molecule occupied a part of the active site that overlaps with the phosphate-binding region in the OMP-or UMP-bound complexes. Space occupied by the pyrimidine and ribose rings of OMP or UMP was not occupied by this inhibitor. The carboxyl group of the inhibitor caused a dramatic movement of the L1 and L2 loops that play a role in the recognition of the substrate and product molecules. Combining part of the inhibitor molecule with moieties of the pyrimidine and ribose rings of OMP and UMP represents a suitable avenue for further development of anti-malarial drugs.
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There are an estimated 300500 million cases of malaria, and up to three million people die of this disease annually. Plasmodium falciparum is the causative agent of the most lethal and severe form of human malaria (1) . The chemotherapy for the treatment of malaria is available but is complicated by both adverse side-effects and widespread resistance to most of the currently available anti-malarial drugs (2, 3). Thus, more efficacious and less toxic agents that specifically target the parasite are required. The malaria parasite depends on de novo synthesis ( Supplementary Fig. 1 ) of pyrimidine nucleotides, whereas humans can synthesize these nucleotides by both de novo and salvage pathways (46). The final two steps of uridine 5 0 -monophosphate (UMP) synthesis require the addition of ribose 5-phosphate from 5-phosphoribosyl-1-pyrophosphate to orotic acid by orotate phosphoribosyltransferase (EC 2.4.2.10) to form orotidine 5 0 -monophosphate (OMP). Subsequently, decarboxylation of OMP by OMP decarboxylase (OMPDC; EC 4.1.1.23) forms UMP. In most prokaryotes and in the malaria parasite, both the enzymes are encoded by two separate genes (7, 8) . Our previous studies demonstrated that the two enzymes exist as a heterotetrameric (orotate phosphoribosyltransferase) 2 (OMPDC) 2 complex in two species of malaria, P. falciparum and Plasmodium berghei (9, 10). In contrast, these genes found in most multicellular organisms, including humans, are fused as a single gene, resulting in the bifunctional UMP synthase (1113).
One of the most important problems associated with in silico screening methods is the prediction of the structures of the protein-ligand complexes. The standard approach involves selecting a chemical compound as a drug candidate based on docking scores. However, the hit rate is usually low in vivo and in vitro. In some cases, particular chemical compounds that have high docking scores for a target protein also display relatively high scores for other proteins, thereby reducing the selectively for the target protein. Fukunishi and Nakamura have developed a multiple target screening (MTS) (14) method that uses a matrix of DG containing several million compounds and several hundred protein structures to select the candidates that most strongly interact with the target protein among the protein list in the matrix. Moreover, the docking score index (DSI) (15) method was developed as a method for screening similar compounds, using the matrix-like MTS method.
In this study, 14 inhibitors for PfOMPDC were selected using the novel in silico screening methods. The crystal structure of PfOMPDC in complex with one of the inhibitors, 4-(2-hydroxy-4-methoxyphenyl)-4-oxobutanoic acid (HMOA), was solved at 2.1 Å resolution. We relate the large structural changes of the loops to the recognition of the substrate or product molecules, and thus provide structural insights for further development of an effective inhibitor.
Materials and Methods
Expression and purification of PfOMPDC Orotidine 5 0 -monophosphate decarboxylase from Plasmodium falciparum (PfOMPDC) was expressed in Escherichia coli BL21(DE3)pLysS (Novagen) as previously described (16) . The E. coli cells were disrupted by sonication with 5 mM Tris-HCl buffer (pH 8.0) containing 50 mM NaCl, 1 mM imidazole and a protease inhibitor cocktail (Roche). The sample was applied to a Ni 2þ -loaded HiTrap chelating HP (GE Healthcare) column equilibrated with buffer A (50 mM Tris-HCl [pH 8.0], 500 mM NaCl and 10 mM imidazole). His-tagged proteins were eluted with a 10500 mM imidazole linear gradient in buffer A. The fractions containing PfOMPDC were pooled and applied to a HiLoad 16/60 Superdex 75 column (GE Healthcare), which was equilibrated with buffer B (50 mM TrisHCl [pH 8.0], 300 mM NaCl and 5 mM dithiothreitol [DTT] ). The purified protein was concentrated to 10 mg mL À1 using an ultracentrifugation concentrator (Sartorius) and was stored at 193 K until crystallization experiments. Up to 12 mg of purified PfOMPDC was obtained from 9 L of the E. coli cell culture.
In silico screening By using a one million compound library with molecular weights of 5350 Da, the inhibitor candidates for PfOMPDC were first selected using both the MTS (14) and DSI (15) methods. The structure of PfOMPDC with the substrate OMP was used (PDB code 2ZA1) during the trial of in silico screening. Subsequently, the scoring function using the molecular mechanics PoissonBoltzmann surface area method (17) was used to evaluate the docking results and to rank the ligand-binding affinities. 200 highest-scoring compounds were ordered as the candidates in total. (Namiki Shoji Co., Ltd.).
SPR analysis
All experiments were performed using an AP-3000 system (Label-free Affinity Perceptive System) (Fuji Photo Film Co. Ltd.). The solution of 0.1 mg mL À1 PfOMPDC diluted in 10 mM sodium acetate buffer (pH 5.5) was immobilized onto the surface of a sensor stick through amine chemistry according to standard procedures. Briefly, a 50:50 solution of 0.1 M N-hydroxysuccinimide and 0.4 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride was injected over the stick surface at 10 mL min À1 for 7 min. The sample solution was then flowed over the activated surface. The remaining activated sites were quenched by flowing 1 M ethanolamine and then washed once with 10 mM HEPES buffer (pH 7.4) over the chip surface at 5 mL sec À1 for 15 min. The two solutions were prepared in 10 mM HEPES buffer (pH 7.4) containing 250 mM DTT and 0.5 or 1.5% dimethyl sulfoxide. These solutions were used for calibration and were injected as the running buffer (10 mM HEPES [pH 7.4], 250 mM DTT and 1% dimethyl sulfoxide). Each compound was diluted in running buffer and applied in the range of 3.9500 mM at 5 mL sec À1 for 15 min. The temperature was kept at 295 K.
IC 50 assays for decarboxylation of PfOMPDC An inhibition assay of candidate compounds for PfOMPDC was performed as described previously (9) . Briefly, the reaction mixture (1 mL) was prepared in 50 mM TrisHCl buffer (pH 8.0) containing 250 mM DTT. The enzyme (550 mL) was incubated for 1 min at 310 K. The reaction was then started by the addition of 250 mM OMP and followed through a linear progress curve of absorbance change at 285 nm up to 36 min. The difference of the extinction coefficients at 285 nm between OMP and UMP was 1.65 Â 10 3 M À1 cm À1 (18) .
Data collection and processing
The crystal of PfOMPDC in complex with the HMOA did not appear using previous crystallization conditions (16) . A novel crystal of apo PfOMPDC was grown by the hanging-drop vapor-diffusion method at 293 K within 1 day. A drop consisted of 1 mL of the protein solution (10 mg ml À1 PfOMPDC, 50 mM TrisHCl [pH 8.0], 300 mM NaCl and 5 mM DTT) with 1 mL of the reservoir solution (100 mM Tris-HCl [pH 8.0], 27% PEGmme 2K and 3% 1,6-hexandiol). To prepare the PfOMPDC-HMOA complex, the crystal was soaked into an HMOA-containing cryoprotectant solution (100 mM Tris-HCl (pH 8.0), 27% PEGmme 2K, 20% glycerol, 3% 1,6-hexandiol and 3.3 mM HMOA) for 2 min.
X-ray diffraction data of the inhibitor complex were collected at the BL38B1 beamline (SPring-8, Japan). The crystal was mounted on a standard nylon loop in a stream of nitrogen at 100 K. The diffraction patterns were recorded on an ADSC Quantum 315 CCD detector. The diffraction intensity data were processed and scaled using HKL2000 (19) . The statistics of the diffraction data collection are shown in Table I .
Structure determination and refinement The molecular replacement calculations were performed with the program MOLREP (20) in the CCP4 program package (21), using the OMP-complex structure of PfOMPDC (PDB code 2ZA1) as the search model. A dimer molecule was contained in an asymmetric unit of the crystal. The electron density map was improved by density modification and non-crystallographic symmetry averaging using DM (22) . Structure models were refined against the diffraction data using CNS (23) and REFMAC5 (24) . Visualization of electron density and model building were performed using Coot (25).
Results and Discussion
Inhibitor search by in silico screening methods To find novel anti-malarial drugs, 5,000 compounds from the one million compound library were screened using either the MTS (14) or DSI (15) methods, respectively. Among the 10,000 compounds screened, 2,378 were selected by both methods. As a result, 7,622 compounds were selected in total. The ligandbinding affinities between the protein and selected candidates were computed using the molecular mechanics PoissonBoltzmann surface area (17) method. The highest scoring 200 compounds with jDGj values in the range of 20130 kcal mol 1 were selected; 156 of these compounds could be obtained commercially (Fig. 1) . The mean value and the standard deviation of the scores for the highest scoring 200 compounds were À23.7 and 3.1 kcal mol 1 , respectively. Although the compounds ranked from 3603 to 7622 had more than 0 kcal mol 1 of DG values, the values for the rest of compounds that ranked from 201 to 3602 were À8.4 and 5.1 kcal mol 1 , respectively. Of these 156 compounds, 43 exhibited the affinity for PfOMPDC at 500 mM with SPR analyses. Finally, 14 inhibitors were found to have potent competitive inhibition 250 mM as determined by IC 50 assays (Fig. 2) . Generally, the hit rate of in silico screening is about 110%, which is higher than that of the highthroughput screening method (0.01%) (26) . In the present study, 14 out of 156 purchased compounds were identified as inhibitor candidates for PfOMPDC, giving a hit rate of 9%. Consequently, our in silico screening methods displayed a 1,000-fold higher hit rate when compared with the high-throughput screening method. However, the scores of in silico screening did not seem to relate to IC 50 values.
X-ray structural analysis of PfOMPDC in complex with HMOA We attempted to crystallize PfOMPDC with the 14 selected compounds, using both the soaking and co-crystallization methods. After many trials, we succeeded with the X-ray structural analysis of PfOMPDC in complex with HMOA (compound 1 in Fig. 2) , which exhibited an IC 50 value of 170 mM. The crystal structure was refined at 2.1 Å resolution with R work of 19.5% and R free of 26.8% (Table I ). The asymmetric unit contained a dimer of PfOMPDC molecules, and superimposition of the two molecules showed a small root mean square deviation of 0.53 Å for the whole 318 C a carbon atoms. This observation reveals similarity of the whole structure in the crystal packing (Fig. 3A) .
The soaking time of the crystal into the HMOA-containing cryoprotectant solution was limited to 2 min to prevent the decay of the crystal. As a result, the electron density around carboxyl group of Fig. 2 Fourteen inhibitor candidates for PfOMPDC. The scores for in silico screening and IC 50 value for each compound were shown in brackets, respectively. The PfOMPDC structure complexed with compound 1 was solved in this study. *The docking score is not shown because of the lack of the stable structure among the binding prediction (docking). Fig. 1 Schematic representation of the strategy for in silico screening. The inhibitor candidates for PfOMPDC were selected from a one million compound library using the MTS and DSI methods. The selected compounds were then measured by SPR analysis and IC 50 assays. Values in parentheses are for the highest resolution shell (2.142.10 Å ).
, where I i (hkl) is the ith intensity measurement and 5I(hkl)4 is the mean of all measurements of I(hkl).
b R work ¼ P hkl jjF obs j À jF calc jj/ P hkl jF obs j calculated from 95% of the data, which were used during the course of the refinement. c R free ¼ P hkl jjF obs j À jF calc jj/ P hkl jF obs j calculated from 5% of the data, which were used during the course of the refinement.
The inhibitor complex of P. falciparum OMP decarboxylase HMOA was relatively weaker than around the aromatic ring of the inhibitor. The B-factor of the HMOA molecule was calculated to be 69.4 Å 2 , which is relatively higher than the surrounding residues with an average B-factor of 28.3 Å 2 . However, the electron density of the HMOA molecule was confirmed in each monomer in the asymmetric unit (Fig. 3B) .
The HMOA complex showed that the carboxyl group of the inhibitor hydrogen bonded to both Gln269 in the L1 loop and Thr195 in the L2 loop. The carbonyl group of the inhibitor hydrogen bonded to both the main chain of Gln269 and a water molecule, and the hydroxyl group hydrogen bonded to the amide nitrogen atom of Ile266. There was a cation-p interaction between the aromatic ring of HMOA and the side chain of Arg294. van der Waals' interactions were also found between the hydroxyl group of HMOA and the N d nitrogen atom of Asn291, and between the methoxy group and the N d nitrogen and the O d oxygen atoms of Asn291. The methoxy group also formed a hydrogen bond with Asp23.
Structural comparison of the HMOA complex with the apo form and the OMP or UMP-complex Superimposition between the HMOA complex and the apo form (28) revealed that the binding of HMOA caused structural changes to the L1 and L2 loops (Fig. 4) . Although the structure of the L1 loop was disordered in the apo form (PDB code 2ZA2), in the HMOA complex, this loop was stabilized by a hydrogen bond between the carboxyl group of the inhibitor and Gln269 in the L1 loop. In addition, Thr195 dramatically rotated to interact with the same carboxyl group of the inhibitor, inducing a conformational change to the L2 loop. The C a carbon atom of Thr195 in the apo form had moved by 2.7 Å and the dihedral angle of the C a -C b bond in Thr195 had changed by 169 on binding of the inhibitor. In our previous work, the structure of the a9 helix (Ala200-Gln203) was completely unfolded on binding of OMP or UMP (28) . In the HMOA complex, however, the structure of the a9 helix was not fully unfolded. The distance between the carbonyl oxygen atom of Ser199 and the amide nitrogen atom of Gln203 was measured to be 3.0 Å in the apo form, whereas in the HMOA complex, the distance was 3.6 Å . The same distance is 4.3 Å in the OMP or UMP complex. The structure of the a9 helix in the HMOA complex appears to be in an intermediate state between the apo and holo forms. Among 14 inhibitor compounds, 11 compounds have a carboxyl group. Before solving the structure of the HMOA complex, the carboxyl group of HMOA was expected to bind in the active site where the phosphate group of OMP or UMP bound (28) by using the in silico screening methods ( Supplementary  Fig. 2 ). However, this carboxyl group interacted with both the L1 and L2 loops, and these loops are distal 4 Structural comparison of the HMOA-complex with the apo form and the OMP-complex. The apo form, the HMOA-complex and the holo form (the OMP-complex) are coloured white, pink and green, respectively. Although the L1 loop structure was disordered in the apo form, the loop was stabilized by a hydrogen bond between the carboxyl group of HMOA and Gln269. Thr195 dramatically rotated to interact with the same carboxyl group of the inhibitor along thereby inducing a structural change to the L2 loop on binding HMOA. This figure was drawn with PyMOL (27).
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from the phosphate bound region. Instead, the aromatic ring of the inhibitor bound in the phosphate binding site of the OMP or UMP complex. In the HMOA complex, there was no electron density around the region where the pyrimidine and the ribose rings were bound in the OMP or UMP complex. Instead, four water molecules occupied the space where the pyrimidine and the ribose rings bind. In the complex structure with OMP or UMP, the amide nitrogen atom and the hydroxyl group of Thr195 interact with O4 and N3 in the pyrimidine ring, respectively. Moreover, Thr145 in the a7 helix in the other protomer of the dimer stabilize the 2 0 -hydroxyl group in the ribose ring (28) .
Compared with the OMP or UMP molecules, the lack of the pyrimidine and the ribose rings in the HMOA molecule may reduce the inhibition activity, therefore giving rise to the observed modest IC 50 value of 170 mM. The Ki value of UMP for PfOMPDC was estimated to 210250 mM (10, 29) . UMP is the product of OMPDC and known to very weakly inhibit OMPDC. For further design and development of inhibitors against this enzyme, the HMOA molecule will be combined with pyrimidine and ribose ring moieties, thereby fully occupying the active site and stabilizing the inhibitor-protein complex. Structural analyses of the other 13 inhibitor-protein complexes are in progress. The completion of the structures of these complexes will advance fragment-based drug design and structure-based drug design against malaria.
Protein Data Bank accession numbers
The atomic coordinates and structure factors of PfOMPDC in complex with HMOA have been deposited in the RCSB Protein Data Bank with the accession code 3VI2.
Supplementary Data
Supplementary Data are available at JB Online.
